Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
July 9, 2025
A conserved editing mechanism for the fidelity of bacterial cell wall biosynthesis
Shambhavi Garde, Harikrishnan Selvaraj, Aakash Chandramouli, et al.
Mbio
|
February 15, 2022
Structural Basis for the Peptidoglycan-Editing Activity of YfiH
Meng-Sheng Lee, Kan-Yen Hsieh, Chiao-I Kuo, et al.
Investigational New Drugs
|
July 26, 2012
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
Gary Hudes, Scott T Tagawa, Young E Whang, et al.
Investigational New Drugs
|
February 19, 2011
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma
Steven J O'Day, Anna C Pavlick, Mark R Albertini, et al.
Cancer Chemotherapy and Pharmacology
|
March 19, 2015
Dose selection of siltuximab for multicentric Castleman's disease
Christina L Mayer, Lanyi Xie, Rajesh Bandekar, et al.
British Journal of Clinical Pharmacology
|
April 8, 2015
Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6
Shalini Chaturvedi, Derick Siegel, Carrie L Wagner, et al.
The Journal of Dermatology
|
June 12, 2010
Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters
Manjula Reddy, Gisela Torres, Thomas McCormick, et al.
American Journal of Hematology
|
June 4, 2014
A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome
Guillermo Garcia-Manero, Gary Gartenberg, David P Steensma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2015
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease
Corey Casper, Shalini Chaturvedi, Nikhil Munshi, et al.
The Prostate
|
February 16, 2011
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study
Jayaprakash Karkera, Hannes Steiner, Weimin Li, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
Proceedings of the National Academy of Sciences of the United States of America
|
July 9, 2025
A conserved editing mechanism for the fidelity of bacterial cell wall biosynthesis
Shambhavi Garde, Harikrishnan Selvaraj, Aakash Chandramouli, et al.
Mbio
|
February 15, 2022
Structural Basis for the Peptidoglycan-Editing Activity of YfiH
Meng-Sheng Lee, Kan-Yen Hsieh, Chiao-I Kuo, et al.
Investigational New Drugs
|
July 26, 2012
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
Gary Hudes, Scott T Tagawa, Young E Whang, et al.
Investigational New Drugs
|
February 19, 2011
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma
Steven J O'Day, Anna C Pavlick, Mark R Albertini, et al.
Cancer Chemotherapy and Pharmacology
|
March 19, 2015
Dose selection of siltuximab for multicentric Castleman's disease
Christina L Mayer, Lanyi Xie, Rajesh Bandekar, et al.
British Journal of Clinical Pharmacology
|
April 8, 2015
Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6
Shalini Chaturvedi, Derick Siegel, Carrie L Wagner, et al.
The Journal of Dermatology
|
June 12, 2010
Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters
Manjula Reddy, Gisela Torres, Thomas McCormick, et al.
American Journal of Hematology
|
June 4, 2014
A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome
Guillermo Garcia-Manero, Gary Gartenberg, David P Steensma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2015
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease
Corey Casper, Shalini Chaturvedi, Nikhil Munshi, et al.
The Prostate
|
February 16, 2011
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study
Jayaprakash Karkera, Hannes Steiner, Weimin Li, et al.
Page
of 5